<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743040</url>
  </required_header>
  <id_info>
    <org_study_id>1038-001</org_study_id>
    <nct_id>NCT01743040</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases</brief_title>
  <acronym>TURBULENCE</acronym>
  <official_title>Pivotal Study of the CADence Device in Detection of Coronary Artery Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AUM Cardiovascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AUM Cardiovascular, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, non-randomized, double-blinded trial to evaluate the
      sensitivity and specificity of the CADence device in detecting the existence of clinically
      significant coronary artery disease as determined by either standard or CT angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, non-randomized, double-blinded, trial to evaluate the
      performance of the CADence in detecting the existence of at least one major coronary artery
      with clinically significant stenosis in a subject is defined as the presence of at least one
      lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid
      Left anterior Descending, proximal Left Circumflex, mid Left Circumflex , proximal Right
      Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1,
      Obtuse Margin 2, and Ramus Intermedius if segment diameter &gt;2.5 mm or ≥50% diameter stenosis
      in the Left Main coronary arteries.

      Consented subjects will be evaluated with the CADence device and then undergo nuclear stress
      testing followed by either computed tomography or standard coronary angiography. The maximum
      expected timeframe between CADence and computed tomography Angiography or standard
      angiography is 6 weeks.

      This is a double-blinded study. All physicians and subjects will be masked to the diagnostic
      results of the CADence until completion of CADence, nuclear stress, computed tomography or
      standard coronary angiogram testing for the subjects. Patient care will not be based on the
      CADence results.

      Study participation will conclude after the computed tomography angiography or standard
      coronary angiography procedure.

      computed tomograph or standard coronary angiography are considered acceptable clinical
      reference standards in this study and are gold standards for detection of coronary artery
      disease. The experimental unit of this study is the subject. Existence of clinically
      significant coronary artery disease in a subject is defined as the presence of at least one
      lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid
      Left anterior Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right
      Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1,
      Obtuse Margin 2, and Ramus Intermedius if segment diameter &gt;2.5 mm or ≥50% diameter stenosis
      in the Left Main coronary arteries.

      The study required sample size is 826 but may enroll up to 1,300 subjects. The sensitivity
      and specificity of the CADence are expected to be 80% and 73% respectively. Observed
      sensitivity and specificity will be compared to nuclear stress literature-based performance
      standards of 83% and 80% respectively using one sample non-inferiority binomial tests with a
      non-inferiority margin of 15 percentage points. Sample size requirements are 109 subjects
      with the presence of at least one lesion with ≥ ≥ 70% diameter stenosis anywhere in the
      proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex,
      mid Left Circumflex, proximal Right Coronary Artery, mid Right Coronary Artery, distal Right
      Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment
      diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left MAIN coronary arteries. to test the
      sensitivity hypothesis and 268 subjects without the presence of at least one lesion with ≥
      70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior
      Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery,
      mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2,
      and Ramus Intermedius if segment diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left MAIN
      coronary arteries. to test the specificity hypothesis. It was assumed that 15 percent of
      enrolled subjects would be found to have the presence of at least one lesion with ≥ 70%
      diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior
      Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery,
      mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2,
      and Ramus Intermedius if segment diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left Main
      coronary arteries. In order to accrue 109 subjects with significant Coronary Artery Disease
      as defined in the protocol, 826 subjects must be enrolled. Sample sizes provide 85% power
      with alpha of 0.05 for each statistical test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2013</start_date>
  <completion_date type="Actual">February 10, 2016</completion_date>
  <primary_completion_date type="Actual">February 10, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of CADence to Detect Stenosis Relative to SPECT Performance, Using Either CT or Standard Angiogram as the Gold Standard</measure>
    <time_frame>No more than 3 weeks between CADence, SPECT and standard or CT angiogram</time_frame>
    <description>The CADence will be considered to have demonstrated effectiveness in detecting the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending (pLAD), mid Left anterior Descending (mLAD), proximal Left Circumflex (pLCx), mid Left Circumflex (mLCx), proximal Right Coronary Artery (pRCA), mid Right Coronary Artery (mRCA), distal Right Coronary Artery (dRCA) and Obtuse Margin 1 (OM1), Obtuse Margin 2 (OM2), and Ramus Intermedius (RI) if segment diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries if sensitivity and specificity are non-inferior within 15 percentage points to a sensitivity of 83% and a specificity of 80%, which is the literature-based Objective Performance Criteria (OPC) for nuclear stress tests.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1014</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CADence plus Standard Angiogram</arm_group_label>
    <description>All patients who were indicated for angiogram due to results of SPECT nuclear stress test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CADence plus CT Angiogram</arm_group_label>
    <description>All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CADence</intervention_name>
    <description>Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.
CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report.</description>
    <arm_group_label>CADence plus CT Angiogram</arm_group_label>
    <arm_group_label>CADence plus Standard Angiogram</arm_group_label>
    <other_name>CT Angiogram</other_name>
    <other_name>Angiogram</other_name>
    <other_name>Nuclear Stress Test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All enrolled subjects that received nuclear stress testing and either CT or standard
        coronary angiography after the CADence evaluation will be included in the analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects clinically indicated for nuclear stress test and who satisfy all the inclusion and
        exclusion criteria are eligible for participation.

        Inclusion criteria:

        Age 22 years or older Willing and able to give informed consent Clinical indication for
        nuclear stress test evaluation Chest pain syndrome

        Two or more coronary artery disease risk factors as defined by:

          1. Dyslipidemia: low-density lipoprotein (LDL) &gt;130 mm/dL or high-density lipoprotein
             (HDL) &lt;35 mm/dL or on treatment for dyslipidemia

          2. Hypertension: blood pressure &gt;140 millimeter of mercury (mmHg) systolic, &gt;90 mmHg
             diastolic or on blood pressure altering treatment

          3. Obesity: body mass index (BMI)&gt;28

          4. Current cigarette smoking

          5. Diabetes: Type 1 or 2

          6. Family history: coronary disease in a first or second degree relative

        Exclusion criteria:

        Body Mass Index (BMI)&lt;18.5 or BMI &gt;40

        Known coronary disease as defined as:

        Prior bypass surgery or coronary stenting Q-wave infarction on a past electrocardiogram
        (EKG) (&gt;0.01 sec Q-wave duration in two adjacent leads)

        Presence of pacemaker/defibrillator Presence of artificial valve Presence of obvious
        cyanotic or pre-diagnosed congenital heart defect and coarctation of the aorta Presence
        murmurs including valve lesions, ventricular septal defects, and arteriovenous (AV)
        fistulae.

        Presence of moderate or severe valve disease as defined by &gt;1/6 heart murmur on physical
        diagnosis Left Ventricular Assist Device (LVAD) Presence of scars on the site thorax areas
        Participation in trial within 30 days prior to collecting CADence data except participation
        in registry studies Asthma with wheezing Inability to lie flat in the supine position Acute
        coronary syndrome with elevated cardiac biomarkers (troponin (TP)&gt;3x upper limit of normal
        (ULN) or creatine kinase MB (CKMB) &gt;3x ULN) Heart Transplant Current cocaine use (within
        the past 24 hours, as reported by subject) Chronic Obstructive Pulmonary Disease (COPD)
        Contraindication to computed tomography (CT) angiography

          -  Renal failure with glomerular filtration rate (GFR)&lt;50 (angio risk)

          -  Iodinated contrast allergy

          -  Elevated heart rate which cannot be controlled sufficiently to achieve a good computed
             tomography angiogram

          -  Body weight &gt;350lbs.

          -  Sinus rhythm rate greater than 100 beats per minute at screening.

          -  Atrial fibrillation with average heart rate of greater than 70 beats per minute on
             resting screening electrocardiogram (ECG).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Thomas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott/Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart &amp; Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast - St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Clinic</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Ohio Research</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster General</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <results_first_submitted>July 7, 2017</results_first_submitted>
  <results_first_submitted_qc>July 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Nuclear Stress Test</keyword>
  <keyword>CT Angiography</keyword>
  <keyword>Angiography</keyword>
  <keyword>CADence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was held June 14, 2013 through February 10, 2016 at hospitals, clinics and research centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All patients enrolled in TURBULENCE study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1014"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CADence Testing</title>
              <participants_list>
                <participants group_id="P1" count="1013"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Nuclear Stress Test</title>
              <participants_list>
                <participants group_id="P1" count="992"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CT and/or Standard Angiogram</title>
              <participants_list>
                <participants group_id="P1" count="785"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="785"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline information was not provided for 3 of the 1,014 participants enrolled due to investigator withdrawals.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All patients enrolled in TURBULENCE study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1011"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.14" spread="10.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="486"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="728"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity and Specificity of CADence to Detect Stenosis Relative to SPECT Performance, Using Either CT or Standard Angiogram as the Gold Standard</title>
        <description>The CADence will be considered to have demonstrated effectiveness in detecting the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending (pLAD), mid Left anterior Descending (mLAD), proximal Left Circumflex (pLCx), mid Left Circumflex (mLCx), proximal Right Coronary Artery (pRCA), mid Right Coronary Artery (mRCA), distal Right Coronary Artery (dRCA) and Obtuse Margin 1 (OM1), Obtuse Margin 2 (OM2), and Ramus Intermedius (RI) if segment diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries if sensitivity and specificity are non-inferior within 15 percentage points to a sensitivity of 83% and a specificity of 80%, which is the literature-based Objective Performance Criteria (OPC) for nuclear stress tests.</description>
        <time_frame>No more than 3 weeks between CADence, SPECT and standard or CT angiogram</time_frame>
        <population>Per protocol subjects who completed all required testing and had analyzable results. Both Sensitivity and Specificity were assessed in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All patients enrolled in TURBULENCE study</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of CADence to Detect Stenosis Relative to SPECT Performance, Using Either CT or Standard Angiogram as the Gold Standard</title>
          <description>The CADence will be considered to have demonstrated effectiveness in detecting the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending (pLAD), mid Left anterior Descending (mLAD), proximal Left Circumflex (pLCx), mid Left Circumflex (mLCx), proximal Right Coronary Artery (pRCA), mid Right Coronary Artery (mRCA), distal Right Coronary Artery (dRCA) and Obtuse Margin 1 (OM1), Obtuse Margin 2 (OM2), and Ramus Intermedius (RI) if segment diameter &gt;2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries if sensitivity and specificity are non-inferior within 15 percentage points to a sensitivity of 83% and a specificity of 80%, which is the literature-based Objective Performance Criteria (OPC) for nuclear stress tests.</description>
          <population>Per protocol subjects who completed all required testing and had analyzable results. Both Sensitivity and Specificity were assessed in this study.</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="76.1" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="32" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The goal was to test the Sensitivity and specificity of CADence as compared to SPECT nuclear stress test OPC. Both were measured and reported in this study. The Sensitivity of CADence was 78% (95% CI 76.1-90.8%) while the specificity was 36% (95% CI 32-39%).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>15% equivalency margin against performance of SPECT nuclear stress test OPC. Both sensitivity and specificity were measured and the equivalency margin was set the same for both parameters.The goal was to test the Sensitivity and specificity of CADence as compared to SPECT nuclear stress test OPC. Both were measured and reported in this study. The Sensitivity of CADence was 78% (95% CI 76.1-90.8%) while the specificity was 36% (95% CI 32-39%).</non_inferiority_desc>
            <p_value>0.012</p_value>
            <method>Exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time CADence data was collected through completion of either their standard or computed tomography (CT) angiogram. The maximum time between CADence and either standard or CT angiogram was 6 weeks.</time_frame>
      <desc>An adverse event is considered serious if: 1) it results in death; 2) is life-threatening; 3) requires subject hospitalization or prolongation of existing hospitalization; 4) results in persistent or significant disability/incapacity; or 5) is an important medical event which may jeopardize the subject and may require medical or surgical intervention to prevent one of the previous outcomes.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>All patients enrolled in TURBULENCE study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
              <event>
                <sub_title>NSTEMI</sub_title>
                <description>Non-ST-Elevation Myocardial Infarction (NSTEMI)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Unknown cause of death, records unavailable. Died in sleep.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Calcaneal Fractures</sub_title>
                <description>Injury from a fall.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Laryngoscopy</sub_title>
                <description>History of vocal paralysis from stroke.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
              <event>
                <sub_title>Knee Replacement</sub_title>
                <description>Right total knee replacement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CCTA-symptomatic bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CCTA-respiratory</sub_title>
                <description>Wheezing/coughing after taking oral &amp; iv metoprolol. Related to history of seasonal allergies and use of metoprolol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CCTA-rash/hives</sub_title>
                <description>Allergic reaction to contrast dye.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CCTA-IV contrast infiltration</sub_title>
                <description>Coronary Computed Tomography Angiography-Intravenous (CCTA-IV) contrast infiltration</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1014"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Thomas, MD</name_or_title>
      <organization>UCLA Biomed</organization>
      <phone>310-222-2544</phone>
      <email>jthomas@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

